These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12188111)

  • 21. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders.
    Duncan JC; Rogers R
    J Forensic Sci; 1998 Nov; 43(6):1133-7. PubMed ID: 9846389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New generation antipsychotic drugs and compliance behaviour.
    Voruganti LP; Baker LK; Awad AG
    Curr Opin Psychiatry; 2008 Mar; 21(2):133-9. PubMed ID: 18332660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Modification of long-term schizophrenia by somato-therapeutic measures].
    Gross G; Huber G; Schüttler R
    Psychiatr Clin (Basel); 1980; 13(3-4):179-92. PubMed ID: 6113621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Compliance in the treatment of schizophrenia--project ADHES (the renewed results)].
    Chadzyńska M; Meder J; Tyszkowska M
    Psychiatr Pol; 2008; 42(4):561-70. PubMed ID: 19189600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.
    Janssen B; Gaebel W; Haerter M; Komaharadi F; Lindel B; Weinmann S
    Psychopharmacology (Berl); 2006 Aug; 187(2):229-36. PubMed ID: 16710714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis.
    Rabinovitch M; Béchard-Evans L; Schmitz N; Joober R; Malla A
    Can J Psychiatry; 2009 Jan; 54(1):28-35. PubMed ID: 19175977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment retention of risperidone long-acting injection in patients with early-onset schizophrenia in Japan.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    Asian J Psychiatr; 2017 Jun; 27():137-138. PubMed ID: 28558887
    [No Abstract]   [Full Text] [Related]  

  • 30. [Relapse in schizophrenia: an exploratory study of the joint conceptions of patients, parents and caregivers].
    Koenig M; Castillo MC; Urdapilleta I; Le Borgne P; Bouleau JH
    Encephale; 2011 Jun; 37(3):207-16. PubMed ID: 21703436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of atypical antipsychotics for substance use in schizophrenia patients.
    Swanson J; Van Dorn RA; Swartz MS
    Schizophr Res; 2007 Aug; 94(1-3):114-8. PubMed ID: 17587548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.
    Valenstein M; Ganoczy D; McCarthy JF; Myra Kim H; Lee TA; Blow FC
    J Clin Psychiatry; 2006 Oct; 67(10):1542-50. PubMed ID: 17107245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Negative vs. positive therapy expectations and compliance vs. noncompliance].
    Linden M
    Psychiatr Prax; 1987 Jul; 14(4):132-6. PubMed ID: 2887002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The natural course of schizophrenia and effective maintenance drug treatment.
    Davis JM; Andriukaitis S
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [What information do patients with schizophrenia have about their illness and treatment?].
    Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
    Encephale; 2000; 26(5):30-8. PubMed ID: 11192802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic treatment with neuroleptics. II: Subjective mechanisms of effect, compliance and consequences for treatment strategy].
    Krausz M; Sorgenfrei T
    Psychiatr Prax; 1991 Jan; 18(1):14-20. PubMed ID: 1674155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years.
    Linden M; Godemann F; Gaebel W; Köpke W; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Schizophr Bull; 2001; 27(4):585-96. PubMed ID: 11824485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year outcome of schizophrenic patients--the interaction of chronicity and neuroleptic treatment.
    Gaebel W; Pietzcker A
    Pharmacopsychiatry; 1985 May; 18(3):235-9. PubMed ID: 2861609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic treatment with neuroleptics. I: State of research on mechanisms of action, effectiveness and compliance in treatment of psychoses].
    Krausz M; Sorgenfrei T
    Psychiatr Prax; 1991 Jan; 18(1):9-13. PubMed ID: 1674156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of non-adherent behaviour in early psychosis.
    Hui CL; Chen EY; Kan CS; Yip KC; Law CW; Chiu CP
    Aust N Z J Psychiatry; 2006 May; 40(5):446-51. PubMed ID: 16683971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.